Literature DB >> 12885894

Stable high-producer cell clone expressing virus-like particles of the Japanese encephalitis virus e protein for a second-generation subunit vaccine.

Asato Kojima1, Atsushi Yasuda, Hideki Asanuma, Toyokazu Ishikawa, Akihisa Takamizawa, Kotaro Yasui, Takeshi Kurata.   

Abstract

We produced and characterized a cell clone (J12#26 cells) that stably expresses Japanese encephalitis virus (JEV) cDNA, J12, which encodes the viral signal peptide, premembrane (prM), and envelope (E) proteins (amino acid positions 105 to 794). Rabbit kidney-derived RK13 cells were transfected with a J12 expression plasmid, selected by resistance to marker antibiotics, and cloned by two cycles of a limiting-dilution method in the presence of antibiotics, a procedure that prevents the successful generation of E-producing cell clones. J12#26 cells secreted virus-like particles containing the authentic E antigen (E-VLP) into the culture medium in a huge enzyme-linked immunosorbent assay-equivalent amount (2.5 micro g per 10(4) cells) to the internationally licensed JE vaccine JE-VAX. E-VLP production was stable after multiple cell passages and persisted over 1 year with 100% expressing cells without detectable cell fusion, apoptosis, or cell death, but was suspended when the cells grew to 100% confluency and contact inhibition occurred. Mice immunized with the purified J12#26 E-antigen without adjuvant developed high titers of neutralizing antibodies for at least 7 months and 100% protection against intraperitoneal challenge with 5 x 10(6) PFU of JEV when examined according to the JE vaccine standardization protocol. These results suggest that the recombinant E-VLP antigen produced by the J12#26 cell clone is an effective, safe, and low-cost second-generation subunit JE vaccine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12885894      PMCID: PMC167253          DOI: 10.1128/jvi.77.16.8745-8755.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998.

Authors:  T F Tsai
Journal:  Vaccine       Date:  2000-05-26       Impact factor: 3.641

2.  Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles.

Authors:  E Konishi; A Fujii; P W Mason
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  Screening of protective antigens of Japanese encephalitis virus by DNA immunization: a comparative study with conventional viral vaccines.

Authors:  H W Chen; C H Pan; M Y Liau; R Jou; C J Tsai; H J Wu; Y L Lin; M H Tao
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

4.  A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen.

Authors:  A R Hunt; C B Cropp; G J Chang
Journal:  J Virol Methods       Date:  2001-09       Impact factor: 2.014

5.  A purified inactivated Japanese encephalitis virus vaccine made in Vero cells.

Authors:  A K Srivastava; J R Putnak; S H Lee; S P Hong; S B Moon; D A Barvir; B Zhao; R A Olson; S O Kim; W D Yoo; A C Towle; D W Vaughn; B L Innis; K H Eckels
Journal:  Vaccine       Date:  2001-08-14       Impact factor: 3.641

Review 6.  Development of new vaccines against dengue fever and Japanese encephalitis.

Authors:  R M Kinney; C Y Huang
Journal:  Intervirology       Date:  2001       Impact factor: 1.763

7.  Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.

Authors:  F Guirakhoo; Z X Zhang; T J Chambers; S Delagrave; J Arroyo; A D Barrett; T P Monath
Journal:  Virology       Date:  1999-05-10       Impact factor: 3.616

8.  A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice.

Authors:  G J Chang; A R Hunt; B Davis
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

9.  Evaluation of the potency of BIKEN inactivated Japanese Encephalitis vaccine and DNA vaccines in an intracerebral Japanese Encephalitis virus challenge.

Authors:  M S Ashok; P N Rangarajan
Journal:  Vaccine       Date:  2000-09-15       Impact factor: 3.641

Review 10.  Structures and mechanisms in flavivirus fusion.

Authors:  F X Heinz; S L Allison
Journal:  Adv Virus Res       Date:  2000       Impact factor: 9.937

View more
  18 in total

1.  Histidine at residue 99 and the transmembrane region of the precursor membrane prM protein are important for the prM-E heterodimeric complex formation of Japanese encephalitis virus.

Authors:  Ying-Ju Lin; Suh-Chin Wu
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

2.  Differential modulation of prM cleavage, extracellular particle distribution, and virus infectivity by conserved residues at nonfurin consensus positions of the dengue virus pr-M junction.

Authors:  Jiraphan Junjhon; Matthawee Lausumpao; Sunpetchuda Supasa; Sansanee Noisakran; Adisak Songjaeng; Prakaimuk Saraithong; Kridsada Chaichoun; Utaiwan Utaipat; Poonsook Keelapang; Amornrat Kanjanahaluethai; Chunya Puttikhunt; Watchara Kasinrerk; Prida Malasit; Nopporn Sittisombut
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103

3.  Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice.

Authors:  S B Justin Wong; Robert F Siliciano
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

4.  Poly-γ-glutamic acid nanoparticles and aluminum adjuvant used as an adjuvant with a single dose of Japanese encephalitis virus-like particles provide effective protection from Japanese encephalitis virus.

Authors:  Shigefumi Okamoto; Hironori Yoshii; Masaaki Matsuura; Asato Kojima; Toyokazu Ishikawa; Takami Akagi; Mitsuru Akashi; Michiaki Takahashi; Koichi Yamanishi; Yasuko Mori
Journal:  Clin Vaccine Immunol       Date:  2011-11-16

5.  Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera frugiperda cells for use as vaccine and diagnostic antigens.

Authors:  Miwa Kuwahara; Eiji Konishi
Journal:  Clin Vaccine Immunol       Date:  2010-07-28

6.  Protective Immune Responses Induced by an mRNA-LNP Vaccine Encoding prM-E Proteins against Japanese Encephalitis Virus Infection.

Authors:  Tao Chen; Shuo Zhu; Ning Wei; Zikai Zhao; Junjun Niu; Youhui Si; Shengbo Cao; Jing Ye
Journal:  Viruses       Date:  2022-05-24       Impact factor: 5.818

7.  Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vector.

Authors:  Travis J Taylor; Fernando Diaz; Robert C Colgrove; Kristen A Bernard; Neal A DeLuca; Sean P J Whelan; David M Knipe
Journal:  Virology       Date:  2016-06-20       Impact factor: 3.616

8.  Hydrophilicity dependent budding and secretion of chimeric HIV Gag-V3 virus-like particles.

Authors:  Lizhong Luo; Yan Li; Soon Duck Ha; C Yong Kang
Journal:  Virus Genes       Date:  2007-05-18       Impact factor: 2.332

9.  Lentiviral-mediated delivery of classical swine fever virus Erns gene into porcine kidney-15 cells for production of recombinant ELISA diagnostic antigen.

Authors:  Supriya Bhattacharya; Mohini Saini; Deepika Bisht; Mashidur Rana; Ram Bachan; Sophia M Gogoi; Bijoy M Buragohain; Nagendra N Barman; Praveen K Gupta
Journal:  Mol Biol Rep       Date:  2019-04-23       Impact factor: 2.742

10.  The prM-independent packaging of pseudotyped Japanese encephalitis virus.

Authors:  Hee Jung Lee; Kyung-Il Min; Jungeun Lee; Sin-Hyung Kang; Wonkyung Jeon; Jae Hwan Nam; Young Ran Ju; Young Bong Kim
Journal:  Virol J       Date:  2009-07-30       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.